Researchers have begun recruiting women in South Africa for the first trials worldwide of a vaginal gel containing an antiretroviral drug, which they hope will protect women from HIV infection. The trials of the microbicide — a gel containing the antiretroviral drug tenofovir, a proven anti-HIV drug in its oral form — are being conducted in the South African province of KwaZulu-Natal.